1-20 of 1036 Search Results for

proton

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Progress in Neurological Surgery
Volume: 32
Published: 23 July 2018
10.1159/000469680
EISBN: 978-3-318-06063-8
... Abstract In comparison to photon irradiation, particle therapy of cancer performed either with protons or with carbon ions, offers the advantage of their distinct physical characteristics, and through delivery of high linear energy transfer (LET) particles, exploits greater relative biological...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350624
EISBN: 978-3-318-02416-6
... Abstract Omeprazole (OPZ), developed by AB Hässle/Astra (Sweden), and lansoprazole (LPZ), developed by Takeda Chemical Industries Ltd. (Japan), were the world's first and second proton pump inhibitors (PPIs), respectively, approved for clinical use in humans. These PPIs have been widely used...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350626
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. There are genetic differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into four...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350628
EISBN: 978-3-318-02416-6
... Abstract During the last two decades the therapeutic superiority of proton pump inhibitors (PPIs) over other drugs has dramatically changed the management of gastroesophageal reflux disease (GERD). Their important clinical efficiency as compared with previous drugs, especially H 2 -receptor...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350629
EISBN: 978-3-318-02416-6
... and complications. This review will focus on the use of proton pump inhibitors (PPIs) in the prevention and healing of NSAID-induced gastroduodenal lesions. The role of PPIs will be compared with alternative gastroprotective agents and placebo. Gastrointestinal (GI) adverse effects of nonsteroidal anti...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350631
EISBN: 978-3-318-02416-6
... Abstract The combination of a proton pump inhibitor (PPI) with two of the following three antibiotics, amoxicillin, clarithromycin, and metronidazole, has been reported to achieve a high eradication rate. These regimens are accepted as standard regimens worldwide. The rationale of PPI-based...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350632
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are effective in preventing recurrent peptic ulcer bleeding when used in high-dose intravenous infusion or oral form. Intermittent injection or low-dose administration of PPIs may not produce such benefit. These findings are based on meta-analysis...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350633
EISBN: 978-3-318-02416-6
... in individual response to stress exist in the background. Acid is considered to be a factor that modifies the manifestation of FD symptoms. Although it has not been proven that excessive gastric acid is present in FD patients, proton pump inhibitors (PPIs) are widely used as first-line drugs in the treatment...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350635
EISBN: 978-3-318-02416-6
... Abstract Proton-pump inhibitors (PPIs) are some of the most widely used drugs in the world. Although the safety of PPIs is well established, there are several side effects, including some which have only recently been recognized. The side effects include diarrhea and various symptoms due...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/000350638
EISBN: 978-3-318-02416-6
... Abstract Proton pump inhibitors (PPIs) are widely used for maintenance treatment of gastroesophageal reflux diseases as well as prevention of gastroduodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs. Since they are used for long periods concurrently with other drugs...
Book
Book Cover Image
Series: Frontiers of Gastrointestinal Research
Volume: 32
Published: 23 September 2013
10.1159/isbn.978-3-318-02416-6
EISBN: 978-3-318-02416-6
Book Chapter
Series: Developments in Ophthalmology
Volume: 49
Published: 24 October 2011
10.1159/000328257
EISBN: 978-3-8055-9791-3
... Abstract Proton beam irradiation of uveal melanoma has great advantages compared to brachytherapy because of the homogenous dose delivered to the tumor and the possibility of sparing normal tissue close to the tumor. We describe the technique of proton beam therapy including the surgical...
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 84
Published: 31 August 2020
10.1159/000457929
EISBN: 978-3-318-06670-8
... to substantially improve tumour control [ 3 , 4 ]. Fig. 1. Holthusen curve. The physicist Robert R. Wilson was the first to propose protons and heavy ions for treatment malignant tumours and pioneered this idea at the Berkeley Radiation Laboratory where more than 2,500 patients were treated...